B. Riley Brokers Reduce Earnings Estimates for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – Stock analysts at B. Riley lowered their FY2025 earnings estimates for Cytokinetics in a report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn ($5.65) per share for the year, down from their prior forecast of ($5.30). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($4.63) EPS and FY2028 earnings at ($2.37) EPS.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley raised shares of Cytokinetics from an “equal weight” rating to an “overweight” rating and reduced their target price for the company from $70.00 to $67.00 in a research note on Thursday, February 13th. Mizuho increased their target price on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Citigroup initiated coverage on shares of Cytokinetics in a research note on Friday, February 7th. They issued a “buy” rating and a $86.00 target price on the stock. Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Trading Up 0.4 %

Shares of CYTK opened at $43.43 on Friday. Cytokinetics has a twelve month low of $40.53 and a twelve month high of $75.71. The company has a market cap of $5.14 billion, a P/E ratio of -8.07 and a beta of 0.95. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The company’s fifty day simple moving average is $46.80 and its 200-day simple moving average is $50.92.

Institutional Trading of Cytokinetics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Cytokinetics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company’s stock valued at $560,520,000 after buying an additional 154,216 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Cytokinetics by 11.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company’s stock valued at $505,780,000 after buying an additional 1,062,136 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cytokinetics by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,848,584 shares of the biopharmaceutical company’s stock valued at $150,433,000 after buying an additional 109,938 shares in the last quarter. Deep Track Capital LP boosted its holdings in shares of Cytokinetics by 296.9% in the 4th quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $117,600,000 after buying an additional 1,870,094 shares in the last quarter. Finally, Vestal Point Capital LP boosted its stake in Cytokinetics by 56.7% in the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock worth $110,544,000 after purchasing an additional 850,000 shares in the last quarter.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 7,300 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.64, for a total transaction of $369,672.00. Following the transaction, the executive vice president now owns 116,071 shares of the company’s stock, valued at approximately $5,877,835.44. This trade represents a 5.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John T. Henderson sold 1,780 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.42, for a total transaction of $89,747.60. Following the transaction, the director now directly owns 38,461 shares in the company, valued at $1,939,203.62. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,133 shares of company stock valued at $1,755,790. Company insiders own 3.40% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.